Home » Stocks » REPH

Recro Pharma, Inc. (REPH)

Stock Price: $3.03 USD 0.06 (2.02%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 70.22M
Revenue (ttm) 74.23M
Net Income (ttm) -25.34M
Shares Out 23.64M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE 18.25
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $3.03
Previous Close $2.97
Change ($) 0.06
Change (%) 2.02%
Day's Open 2.99
Day's Range 2.94 - 3.08
Day's Volume 754,530
52-Week Range 1.51 - 18.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical...

InvestorPlace - 1 month ago

Perhaps this year like no other has demonstrated the yin-yang effect of the market. While we've seen incredible winners, these companies represent the worst performing stocks of 2020.

Other stocks mentioned: AHT, FARM, GLBS, ICD, JE, MITT
Zacks Investment Research - 1 month ago

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

Seeking Alpha - 2 months ago

Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

  Shares of Recro Pharma (NASDAQ:REPH) were unchanged after the company reported Q3 results.

GlobeNewsWire - 2 months ago

Company Secures Three-Year Renewal of Licens e and Supply Agreement with Lannett , A Generic s Pharmaceutical Company, for Manufacturing of Verelan PM ® , Verelan SR ® and Verapamil PM

GlobeNewsWire - 4 months ago

GAINESVILLE, Ga., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development,...

Seeking Alpha - 5 months ago

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of Recro Pharma (NASDAQ:REPH) were flat in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

Launches Clinical Trial Materials Business and Secures New Customers

Forbes - 6 months ago

Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second...

Other stocks mentioned: CNCE, CRDF, IDN, VRTV
Forbes - 6 months ago

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead o...

Other stocks mentioned: BKYI, COCP, EYES, EYPT
GlobeNewsWire - 7 months ago

Company Owns and Operates Over 120,000 Square Feet of U.S. cGMP and DEA-Licensed Contract Development and Manufacturing Facilities Focused on Creating Oral, Solid Dose Drug Products

Zacks Investment Research - 7 months ago

Recro Pharma (REPH) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Seeking Alpha - 8 months ago

Recro Pharma, Inc.'s (REPH) CEO Gerri Henwood on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Recro Capitalizing on Strong and Growing CDMO Business

GlobeNewsWire - 1 year ago

Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets

GlobeNewsWire - 1 year ago

Separation of Baudax Bio as Independent Company Expected to be Completed  With Distribution on November 21, 2019

Seeking Alpha - 1 year ago

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Recro Pharma (REPH) delivered earnings and revenue surprises of -46.15% and 27.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Recro Pharma: FDA Grants Appeal For IV Meloxicam, Adding Value To The Proposed Acute Care Spin-Out

GlobeNewsWire - 1 year ago

Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request

Zacks Investment Research - 1 year ago

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Excluding the IV meloxicam CRL, Recro Pharma has a strong 2019 with cutting OpEx and moving closer to cash flow positive. However, management is looking to spin-out the acute care segment.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Recro Pharma.

Seeking Alpha - 1 year ago

Recro Pharma, Inc. (REPH) CEO Gerri Henwood on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Recro Pharma (REPH) delivered earnings and revenue surprises of 63.89% and 29.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 1 year ago

Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.

Other stocks mentioned: AFMD, ARWR, INCY, RGEN, VCYT, VRTX
InvestorPlace - 1 year ago

These stocks to buy are low-priced, top quality choices for growth. Here's what you need to know about each.

Other stocks mentioned: DHT, FSI, IGC, SACH
Seeking Alpha - 1 year ago

Recro Pharma, Inc. (REPH) CEO Geraldine Henwood on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Recro Pharma (REPH) delivered earnings and revenue surprises of 87.34% and 22.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Recro Pharma (REPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Recro Pharma, Inc. (REPH).

Seeking Alpha - 1 year ago

Recro Pharma recently received its second CRL from the FDA regarding its IV Meloxicam product candidate. As a result, the company has announced a restructuring of its Acute Care Segment.

24/7 Wall Street - 1 year ago

This stock was pounded recently and offers a great entry point.

Benzinga - 1 year ago

Recro Pharma Inc. shares were crashing Monday in reaction to an adverse regulatory decision on its lead pain medication candidate that was announced late Friday.

Market Watch - 1 year ago

Shares of Recro Pharma Inc. plummeted 46% to pace all premarket decliners Monday.

Seeking Alpha - 1 year ago

Recro Pharma, a smallcap U.S. pharma company has a Food and Drug Administration (FDA) decision on its main drug pending on March 24, 2019.

About REPH

Recro Pharma a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Mar 7, 2014
Stock Exchange
NASDAQ
Ticker Symbol
REPH
Full Company Profile

Financial Performance

In 2019, Recro Pharma's revenue was $99.22 million, an increase of 28.28% compared to the previous year's $77.35 million. Losses were -$18.63 million, -76.63% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Recro Pharma stock is "Strong Buy." The 12-month stock price forecast is 5.50, which is an increase of 81.52% from the latest price.

Price Target
$5.50
(81.52% upside)
Analyst Consensus: Strong Buy